Dr. Simon on the Impact of Immunotherapy Agents in NSCLC

George R. Simon, MD, FACP, FCCP
Published: Tuesday, Feb 20, 2018



George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

More recently, there have been reports that after patients complete concurrent chemoradiation regimens for locally advanced NSCLC, giving durvalumab (Imfinzi) for maintenance therapy for about 1 year improved progression-free survival (PFS). The overall survival data are still pending. The improvement in PFS is significantly higher than the administration of chemoradiation alone.

There are other studies that are investigating the use of immunotherapy in these patients such as the use of atezolizumab (Tecentriq). This is the first significant advance in stage III disease that physicians have seen in a while where an intervention has improved survival over concurrent chemoradiation alone.
 


George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

More recently, there have been reports that after patients complete concurrent chemoradiation regimens for locally advanced NSCLC, giving durvalumab (Imfinzi) for maintenance therapy for about 1 year improved progression-free survival (PFS). The overall survival data are still pending. The improvement in PFS is significantly higher than the administration of chemoradiation alone.

There are other studies that are investigating the use of immunotherapy in these patients such as the use of atezolizumab (Tecentriq). This is the first significant advance in stage III disease that physicians have seen in a while where an intervention has improved survival over concurrent chemoradiation alone.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x